RE: Negatives and the Elephant in the room!9 Dec 2022 13:49
Hi Stephen. In answer to the points you raise, these are my thoughts and opinions. I think it's no surprise that GDR will need to secure further funding by the 30th June 2023 prior to any meaningful revenue being received. As Stares has stated, this could well be via convertible bonds. If there is a raise, the optimum window of opportunity would be after the NICE review is completed and the necessary recommendations and approval. Obviously at that stage the SP would be a lot higher and institutional investors would have more assurances for investing their clients funds.
As to the sales and marketing team. Personally I think this is an extremely positive sign. Although GDR distribute via distribution partners, virtually all inquiries will come directly to Genedrive and instead of being fobbed off, all potential clients will be given all the help, information and data they require directly from the company itself. It also allows Genedrive to monitor that valuable inquiry through to fruition. If any potential client hasn't received the information they requested, then it gives GDR the opportunity to report that to Inspiration Health. In effect Stephen, it gives GDR complete control over every single enqiry and potential client for GDR products. It means every single lead that is generated by interest in AIHL is treated with the utmost respect and not wasted and frittered away. Good luck. Atb Popeye